Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions

Retrovirology

Volumn 13, Issue 1, 2016, Pages

  Gasser, Romain ^a   Hamoudi, Meriem ^a,b   Pellicciotta, Martina ^a   Zhou, Zhicheng ^c   Visdeloup, Clara ^d   Colin, Philippe ^c   Braibant, Martine ^d   Lagane, Bernard ^c   Negroni, Matteo ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITÉ DE TOURS   (France)

Author keywords

Antigenic variation; Coevolution; Envelope; HIV; Viral entry

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN GP 120; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; VIRUS ENVELOPE PROTEIN; AMIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; QUATERNARY AMMONIUM DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL ADHESION; COEVOLUTION; CONTROLLED STUDY; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; LOSS OF FUNCTION MUTATION; MEMBRANE FUSION; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN STABILITY; SEQUENCE ANALYSIS; VIRUS ENTRY; VIRUS PARTICLE; ANTIGENIC VARIATION; CHEMISTRY; GENETIC VARIATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SEQUENCE ALIGNMENT;

AMIDES; ANTIGENIC VARIATION; ANTIGENS, CD4; EVOLUTION, MOLECULAR; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; POLYMORPHISM, GENETIC; PROTEIN STABILITY; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; SEQUENCE ALIGNMENT; VIRUS INTERNALIZATION;

EID: 84979659051     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-016-0285-6     Document Type: Article

References (61)

1. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The Cd4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-7.
2. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008;455:109-13.
3. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun CX, Grayson T, Wang SY, Li H, et al. Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552-7.
4. Mild M, Kvist A, Esbjornsson J, Karlsson I, Fenyo EM, Medstrand P. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol. 2010;10:356-64.
5. Pancera M, Zhou TQ, Druz A, Georgiev IS, Soto C, Gorman J, Huang JH, Acharya P, Chuang GY, Ofek G, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514:455.
6. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012;188:5166-76.
7. Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176-86.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-20.
9. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490:417-20.
10. Patel PH, Preston BD. Marked infidelity of human-immunodeficiency-virus type-1 reverse-transcriptase at RNA and DNA-template ends. Proc Natl Acad Sci USA. 1994;91:549-53.
11. Cuevas JM, Geller R, Garijo R, Lopez-Aldeguer J, Sanjuan R. Extremely high mutation rate of HIV-1 in vivo. Plos Biol. 2015;13:e1002251.
12. Baird HA, Galetto R, Gao Y, Simon-Loriere E, Abreha M, Archer J, Fan J, Robertson DL, Arts EJ, Negroni M. Sequence determinants of breakpoint location during HIV-1 intersubtype recombination. Nucleic Acids Res. 2006;34:5203-16.
13. Zhuang JL, Jetzt AE, Sun GL, Yu H, Klarmann G, Ron Y, Preston BD, Dougherty JP. Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol. 2002;76:11273-82.
14. Galetto R, Moumen A, Giacomoni V, Veron M, Charneau P, Negroni M. The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo. J Biol Chem. 2004;279:36625-32.
15. Drummond DA, Silberg JJ, Meyer MM, Wilke CO, Arnold FH. On the conservative nature of intragenic recombination. Proc Natl Acad Sci USA. 2005;102:5380-5.
16. Simon-Loriere E, Rossolillo P, Negroni M. RNA structures, genomic organization and selection of recombinant HIV. RNA Biol. 2011;8:280-6.
17. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1477-83.
18. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342:1484-90.
19. Bartesaghi A, Merk A, Borgnia MJ, Milne JLS, Subramaniam S. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol. 2013;20:1352-7.
20. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-59.
21. Pancera M, Majeed S, Ban YEA, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou TQ, Robinson JE, et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA. 2010;107:1166-71.
22. Hu GQ, Liu J, Taylor KA, Roux KH. Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol. 2011;85:2741-50.
23. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SSU, Stanfield RL, Robinson J, Sodroski J, Wilson IA, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science. 2007;317:1930-4.
24. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem. 1999;274:9617-26.
25. DoKwon Y, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma XC, Narpala S, et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol. 2015;22:522.
26. Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J. 2015;12:3.
27. Galli A, Kearney M, Nikolaitchik OA, Yu S, Chin MPS, Maldarelli F, Coffin JM, Pathak VK, Hu WS. Patterns of human immunodeficiency virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication. J Virol. 2010;84:7651-61.
28. Simon-Loriere E, Galetto R, Hamoudi M, Archer J, Lefeuvre P, Martin DP, Robertson DL, Negroni M. Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. Plos Pathog. 2009;5:e1000418.
29. Hamoudi M, Simon-Loriere E, Gasser R, Negroni M. Genetic diversity of the highly variable V1 region interferes with human immunodeficiency virus type 1 envelope functionality. Retrovirology. 2013;10:114.
30. Scharf L, Scheid JF, Lee JH, West AP, Chen C, Gao H, Gnanapragasam PNP, Mares R, Seaman MS, Ward AB, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014;7:785-95.
31. Scharf L, Wang HQ, Gao H, Chen SY, McDowall AW, Bjorkman PJ. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell. 2015;162:1379-90.
32. West AP, Scharf L, Horwitz J, Klein F, Nussenzweig MC, Bjorkman PJ. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci USA. 2013;110:10598-603.
33. Moore JP, Mckeating JA, Weiss RA, Sattentau QJ. Dissociation of Gp120 from HIV-1 virions induced by soluble CD4. Science. 1990;250:1139-42.
34. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466-U117.
35. Garcia-Perez J, Staropoli I, Azoulay S, Heinrich JT, Cascajero A, Colin P, Lortat-Jacob H, Arenzana-Seisdedos F, Alcami J, Kellenberger E, Lagane B. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology. 2015;12:50.
36. Munro JB, Mothes W. Structure and dynamics of the native HIV-1 Env trimer. J Virol. 2015;89:5752-5.
37. Travers SAA, Tully DC, McCormack GP, Fares MA. A study of the coevolutionary patterns operating within the Env gene of the HIV-1 group M subtypes. Mol Biol Evol. 2007;24:2787-801.
38. Cashin K, Sterjovski J, Harvey KL, Ramsland PA, Churchill MJ, Gorry PR. Covariance of charged amino acids at positions 322 and 440 of HIV-1 Env contributes to coreceptor specificity of subtype B viruses, and can be used to improve the performance of V3 sequence-based coreceptor usage prediction algorithms. Plos One. 2014;9:e109771.
39. Dimonte S, Mercurio F, Svicher V, D'Arrigo R, Perno CF, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120(V3) signatures in the regulation of co-receptor usage. Retrovirol. 2011;8:33.
40. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin N, Petropoulos CJ. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol. 2008;82:5584-93.
41. Lombardi F, Nakamura KJ, Chen T, Sobrera ER, Tobin NH, Aldrovandi GM. A conserved glycan in the C2 domain of HIV-1 envelope acts as a molecular switch to control X4 utilization by clonal variants with identical V3 loops. Plos One. 2015;10:e0128116.
42. Dimonte S, Babakir-Mina M, Mercurio F, Di Pinto D, Ceccherini-Silberstein F, Svicher V, Perno CF. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage. Virus Res. 2012;168:73-83.
43. Geller R, Domingo-Calap P, Cuevas J, Rossolillo P, Negroni M, Sanjuan R. The external domains of the HIV-1 envelope are a mutational cold spot. Nat Commun. 2015;6:8571.
44. Gitlin L, Hagai T, LaBarbera A, Solovey M, Andino R. Rapid evolution of virus sequences in intrinsically disordered protein regions. Plos Pathog. 2014;10:e1004529.
45. Nilsson J, Grahn M, Wright APH. Proteome-wide evidence for enhanced positive Darwinian selection within intrinsically disordered regions in proteins. Genome Biol. 2011;12:R65.
46. Schlessinger A, Schaefer C, Vicedo E, Schmidberger M, Punta M, Rost B. Protein disorder-a breakthrough invention of evolution? Curr Opin Struct Biol. 2011;21:412-8.
47. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, et al. Structure of a V3-containing HIV-1 gp120 core. Science. 2005;310:1025-8.
48. Pancera M, Shahzad-ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai KF, Loesgen S, Louder MK, Staupe RP, Yang YP, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20:804.
49. Brandenberg OF, Magnus C, Rusert P, Regoes RR, Trkola A. Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. Plos Pathog. 2015;11:e1004595.
50. Klasse PJ. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology. 2007;369:245-62.
51. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, Ehlert AK, Regoes RR, Gunthard HF, Trkola A. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med. 2011;208:1419-33.
52. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJV, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JLS, Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. Plos Pathog. 2010;6:e1001249.
53. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human-immunodeficiency-virus type-1 in mononuclear phagocytes. Virology. 1995;206:935-44.
54. Njai HF, Gali Y, Vanham G, Clybergh C, Jennes W, Vidal N, Butel C, Mpoudi-Ngolle E, Peeters M, Arien KK. The predominance of human immunodeficiency virus type I (HIV-I) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology. 2006;3:40.
55. Healey D, Dianda L, Moore JP, Mcdougal JS, Moore MJ, Estess P, Buck D, Kwong PD, Beverley PCL, Sattentau QJ. Novel anti-Cd4 monoclonal-antibodies separate human-immunodeficiency-virus infection and fusion of CD4+ cells from virus binding. J Exp Med. 1990;172:1233-42.
56. Braibant M, Xie J, Samri A, Agut H, Autran B, Barin F. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology. 2010;405:81-92.
57. Montefiori D. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485:395-405.
58. Johnson VA, Byington RE. Infectivity assay (virus yield assay). In: Aldovani A, Walker BD, editors. Techniques in HIV research. New York: Stockton Press; 1990. p. 71-6.
59. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses. 2002;18:567-76.
60. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79:10108-25.
61. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80:11776-90.